Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
DiabetesHealthy
Interventions
DRUG

insulin detemir

Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)

Trial Locations (1)

100032

Novo Nordisk Investigational Site, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY